Rockefeller Capital Management
ACRS icon

Rockefeller Capital Management’s Aclaris Therapeutics ACRS Stock Holding History

Rockefeller Capital Management’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$32.3K Hold
6,112
– – ﹤0.01% 3555
2026
Q1 		$22.9K Buy
6,112
+4,886
+399% +$16.5K ﹤0.01% 3655
2025
Q4 		$3.69K Buy
+1,226
New +$3.1K ﹤0.01% 4159
2020
Q2 		– Sell
-1,000
Closed -$1K – 2565
2020
Q1 		$1K Buy
+1,000
New +$1.36K ﹤0.01% 2247

Other funds holding ACRS

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return

Rockefeller Capital Management's ACRS Position: Q2 2026 in Review

Rockefeller Capital Management held its Aclaris Therapeutics (ACRS) position steady in Q2 2026 at 6,112 shares worth $32.3K. The position accounts for ﹤0.01% of the portfolio, ranked #3555.

Rockefeller Capital Management first reported a position in ACRS in Q1 2020 and has held it in 4 quarters since. 148 funds tracked by Wall St. Rank hold ACRS as of Q2 2026.

  • Rockefeller Capital Management held 6,112 shares of Aclaris Therapeutics worth $32.3K as of Q2 2026.
  • Rockefeller Capital Management left its Aclaris Therapeutics share count unchanged in Q2 2026.
  • Aclaris Therapeutics made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q2 2026, its #3555 holding.
  • Rockefeller Capital Management first reported a position in Aclaris Therapeutics in Q1 2020 and has held it in 4 quarters since.
  • 148 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q2 2026.

Based on Rockefeller Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.